NasdaqGM:TRVIPharmaceuticals
Should Trevi Therapeutics’ (TRVI) Late-Stage Chronic Cough Progress and Strong Cash Position Prompt Investor Action?
Trevi Therapeutics recently announced the advancement of its chronic cough clinical program, reporting reduced net losses for the third quarter and a strong cash position expected to support operations into 2028.
An additional highlight is the successful completion of a large fundraising effort and the company’s growing momentum in pursuing late-stage trials for chronic cough therapies.
We'll explore how Trevi’s robust financial position and progress toward Phase 3 trials for chronic cough...